EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The exponential increase in the number of prescriptions for ADHD medication between 2012 and 2022 in Poland in patients aged 5–59 years: a pharmacoepidemiological study

Marcin Rzeszutek iD, Łukasz Konowałek, Joanna Martin, Agnieszka Butwicka, Tomasz Wolańczyk

European Child & Adolescent Psychiatry · 2026

DOI: 10.1007/s00787-026-03104-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Child & Adolescent Psychiatry, 2026. Verfasst von Marcin Rzeszutek und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Child Psychiatry, Medical University of Warsaw, Żwirki i Wigury 63A, 02-091, Warsaw, Poland. marcin.rzeszutek@wum.edu.pl. Hauptthemen laut MEDLINE: Attention Deficit Disorder with Hyperactivity, Methylphenidate, Atomoxetine Hydrochloride, Central Nervous System Stimulants. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are currently no pharmacoepidemiological data on the use of ADHD medications in Poland. Moreover, evidence from Central and Eastern Europe remains limited, despite a global increase in ADHD diagnosis and pharmacological treatment. This lack of evidence highlights the need for population-based analyses of prescribing trends in this setting. This study aims to analyze data from the Polish prescription register to estimate the increase in the total number of prescriptions for methylphenidate and atomoxetine from 2012 to 2022, as well as identify any factors that may have influenced this trend. A retrospective population-based study utilizing a large electronic database containing all ( n = 925 536) prescriptions for ADHD medication in Poland for the period between 2012 and 2022 for patients aged 5–59 years was conducted. We performed regression-based temporal trend analyses, including age- and sex-stratified interaction models. The prevalence of ADHD medications rose from 170.33 prescriptions per 100 000 in 2012 ( n = 48,429) to 591.50 per 100 000 in 2022 ( n = 155,068), marking a 247% increase. Methylphenidate remained the most prescribed medication, with its prevalence increasing from 168.28 prescriptions per 100,000 in 2012 to 481.45 prescriptions per 100,000 in 2022 (186% increase), while atomoxetine experienced an increase from 2.02 prescriptions per 100,000 in 2012 to 110.05 prescriptions per 100,000 in 2022 (5242% increase). ADHD medication usage increased across all age groups, with the highest prescription rates observed among children aged 7–12 and significant growth seen in adolescents aged 13–17. The use of ADHD medications has increased among all age groups and in males as well as females. The rate of increase was highest among females, particularly in the group of young adults (18–24 year olds). Our study provides data on prescription trends in Poland, contributing to the limited evidence from Central and Eastern Europe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Attention Deficit Disorder with HyperactivityMethylphenidateAtomoxetine HydrochlorideCentral Nervous System StimulantsDrug PrescriptionsHumansPolandChildRetrospective StudiesAdolescentFemaleMaleMiddle AgedChild, PreschoolAdultYoung AdultPharmacoepidemiology

Stichwörter der Autor:innen

AtomoxetineDrug prescriptionsDrug utilizationMethylphenidateTime factors

Substanzen

MethylphenidateAtomoxetine HydrochlorideCentral Nervous System Stimulants

Autor:innen und Institutionen

  • Department of Child Psychiatry, Medical University of Warsaw, Żwirki i Wigury 63A, 02-091, Warsaw, Poland. marcin.rzeszutek@wum.edu.pl.
  • Department of Child Psychiatry, Medical University of Warsaw, Żwirki i Wigury 63A, 02-091, Warsaw, Poland.
  • Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
  • Wolfson Centre for Young People's Mental Health, Cardiff University, Cardiff, UK.
  • Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Division of Mental Health Services, R&D Department, Akershus University Hospital, Lørenskog, Norway.

ORCID-Profile: Marcin Rzeszutek

Zitieren

APA

Rzeszutek, M., Konowałek, Ł., Martin, J., Butwicka, A., & Wolańczyk, T. (2026). The exponential increase in the number of prescriptions for ADHD medication between 2012 and 2022 in Poland in patients aged 5–59 years: a pharmacoepidemiological study. European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-026-03104-5

Vancouver

Rzeszutek M, Konowałek Ł, Martin J, Butwicka A, Wolańczyk T. The exponential increase in the number of prescriptions for ADHD medication between 2012 and 2022 in Poland in patients aged 5–59 years: a pharmacoepidemiological study. European Child & Adolescent Psychiatry. 2026. doi:10.1007/s00787-026-03104-5

BibTeX
@article{Rzeszutek2026,
  author = {Rzeszutek, Marcin and Konowałek, Łukasz and Martin, Joanna and Butwicka, Agnieszka and Wolańczyk, Tomasz},
  title = {The exponential increase in the number of prescriptions for ADHD medication between 2012 and 2022 in Poland in patients aged 5–59 years: a pharmacoepidemiological study},
  journal = {European Child & Adolescent Psychiatry},
  year = {2026},
  doi = {10.1007/s00787-026-03104-5}
}
Kostenlos starten →